NCT06353087 Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)
| NCT ID | NCT06353087 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pfizer |
| Condition | Dermatitis, Atopic |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2026-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-07-01 with a primary completion date of 2026-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.
Eligibility Criteria
Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Patients aged ≥12 years 2. Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician 3. Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions 4. Evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study Exclusion Criteria: Patients meeting any of the following criteria will not be included in the study: 1. Any prior use of abrocitinib 2. Simultaneous participation in a study that includes administration of any investigational drug or procedure
Contact & Investigator
Pfizer CT.gov Call Center
STUDY DIRECTOR
Pfizer
Frequently Asked Questions
Who can join the NCT06353087 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Dermatitis, Atopic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06353087 currently recruiting?
Yes, NCT06353087 is actively recruiting participants. Contact the research team at ClinicalTrials.gov_Inquiries@pfizer.com for enrollment information.
Where is the NCT06353087 trial being conducted?
This trial is being conducted at Kaohsiung City, Taiwan, Kaohsiung City, Taiwan, New Taipei City, Taiwan, Taipei, Taiwan and 4 additional locations.
Who is sponsoring the NCT06353087 clinical trial?
NCT06353087 is sponsored by Pfizer. The principal investigator is Pfizer CT.gov Call Center at Pfizer. The trial plans to enroll 200 participants.